LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Open

SectorGezondheidszorg

67.68 2.92

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

65.29

Max

68.75

Belangrijke statistieken
By Trading Economics
Inkomsten	24M -167M
Verkoop	40M 195M
EPS	-0.84
Winstmarge	-85.626
Werknemers	834
EBITDA	75M -105M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+61.8% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	163M 14B
Vorige openingsprijs	64.76
Vorige sluitingsprijs	67.68

Nieuwssentiment

By Acuity

36%

64%

95 / 344 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 mei 2026, 22:47 UTC

Winsten

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mei 2026, 20:45 UTC

Winsten

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mei 2026, 23:39 UTC

Marktinformatie

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mei 2026, 23:31 UTC

Marktinformatie

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mei 2026, 23:17 UTC

Marktinformatie

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mei 2026, 23:02 UTC

Marktinformatie

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mei 2026, 22:37 UTC

Marktinformatie

Acquisities, Fusies, Overnames

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mei 2026, 21:12 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mei 2026, 21:00 UTC

Winsten

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mei 2026, 20:57 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:55 UTC

Winsten

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

28 mei 2026, 20:48 UTC

Populaire aandelen

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mei 2026, 20:34 UTC

Winsten

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mei 2026, 20:31 UTC

Winsten

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mei 2026, 20:28 UTC

Winsten

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mei 2026, 20:26 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Membership Fees $1.37B

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Net Sales $69.15B

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

61.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.5 USD 61.8%

Hoogste 157 USD

Laagste 82 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

95 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.